Ixempra (Breast Cancer) - Analysis and Forecasts to 2020


#97915

35pages

GlobalData

$ 2000

In Stock

 


GlobalDatas pharmaceuticals report, Ixempra (Breast Cancer) Analysis and Forecasts to 2020 provides Ixempra sales estimates for the US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

 

 

 

  • Therapy area profile including patient population for the US
  • Analysis and review of Ixempra including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Ixempra including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2007-2020 for Ixempra in the US


Reasons to buy

 

 

 

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets


Keywords

Ixempra, Breast Cancer, ixabepilone, Sales forecast,Mitotic Inhibitor, Phase III, Phase 3, Pipeline, Competitors to Xeloda, Taxol and Halaven, Bristol-Myer's squibb